Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries.

Volkova N, Moy K, Evans J, Campbell D, Tian S, Simard C, Higgins M, Konstan MW, Sawicki GS, Elbert A, Charman SC, Marshall BC, Bilton D.

J Cyst Fibros. 2019 Jun 10. pii: S1569-1993(19)30767-2. doi: 10.1016/j.jcf.2019.05.015. [Epub ahead of print]

PMID:
31196670
2.

Gastrointestinal cancers in patients with cystic fibrosis.

Maisonneuve P, Lowenfels AB, Hadjiliadis D, Khoruts A, Marshall BC.

Lancet Oncol. 2018 Aug;19(8):e368. doi: 10.1016/S1470-2045(18)30485-6. No abstract available.

PMID:
30102218
3.

Trans-Atlantic collaboration: applying lessons learned from the US CF Foundation quality improvement initiative.

Sabadosa KA, Godfrey MM, Marshall BC.

Orphanet J Rare Dis. 2018 Feb 8;13(Suppl 1):13. doi: 10.1186/s13023-017-0744-8.

4.

Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor.

Bessonova L, Volkova N, Higgins M, Bengtsson L, Tian S, Simard C, Konstan MW, Sawicki GS, Sewall A, Nyangoma S, Elbert A, Marshall BC, Bilton D.

Thorax. 2018 Aug;73(8):731-740. doi: 10.1136/thoraxjnl-2017-210394. Epub 2018 May 10.

5.

Clinical characteristics of cystic fibrosis patients prior to lung transplantation: An international comparison between Canada and the United States.

Quon BS, Sykes J, Stanojevic S, Marshall BC, Petren K, Ostrenga J, Fink A, Elbert A, Faro A, Goss CH, Stephenson AL.

Clin Transplant. 2018 Mar;32(3):e13188. doi: 10.1111/ctr.13188. Epub 2018 Feb 11.

6.

End-of-life practice patterns at U.S. adult cystic fibrosis care centers: A national retrospective chart review.

Chen E, Homa K, Goggin J, Sabadosa KA, Hempstead S, Marshall BC, Faro A, Dellon EP.

J Cyst Fibros. 2017 Sep 13. pii: S1569-1993(17)30873-1. doi: 10.1016/j.jcf.2017.08.010. [Epub ahead of print]

PMID:
28917611
7.

Data that empower: The success and promise of CF patient registries.

Fink AK, Loeffler DR, Marshall BC, Goss CH, Morgan WJ.

Pediatr Pulmonol. 2017 Nov;52(S48):S44-S51. doi: 10.1002/ppul.23790. Epub 2017 Sep 14. Review.

PMID:
28910520
8.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.

Sanders DB, Solomon GM, Beckett VV, West NE, Daines CL, Heltshe SL, VanDevanter DR, Spahr JE, Gibson RL, Nick JA, Marshall BC, Flume PA, Goss CH; STOP Study Group.

J Cyst Fibros. 2017 Sep;16(5):592-599. doi: 10.1016/j.jcf.2017.04.005. Epub 2017 Apr 29.

9.

Nanosegregation and Structuring in the Bulk and at the Surface of Ionic-Liquid Mixtures.

Bruce DW, Cabry CP, Lopes JNC, Costen ML, D'Andrea L, Grillo I, Marshall BC, McKendrick KG, Minton TK, Purcell SM, Rogers S, Slattery JM, Shimizu K, Smoll E, Tesa-Serrate MA.

J Phys Chem B. 2017 Jun 22;121(24):6002-6020. doi: 10.1021/acs.jpcb.7b01654. Epub 2017 Jun 8.

PMID:
28459567
10.

Survival Comparison of Patients With Cystic Fibrosis in Canada and the United States: A Population-Based Cohort Study.

Stephenson AL, Sykes J, Stanojevic S, Quon BS, Marshall BC, Petren K, Ostrenga J, Fink AK, Elbert A, Goss CH.

Ann Intern Med. 2017 Apr 18;166(8):537-546. doi: 10.7326/M16-0858. Epub 2017 Mar 14.

11.

Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation.

Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, Howenstine M, McColley SA, Rock M, Rosenfeld M, Sermet-Gaudelus I, Southern KW, Marshall BC, Sosnay PR.

J Pediatr. 2017 Feb;181S:S4-S15.e1. doi: 10.1016/j.jpeds.2016.09.064. Erratum in: J Pediatr. 2017 May;184:243.

12.

Resistance of POSS Polyimide Blends to Hyperthermal Atomic Oxygen Attack.

Qian M, Murray VJ, Wei W, Marshall BC, Minton TK.

ACS Appl Mater Interfaces. 2016 Dec 14;8(49):33982-33992. Epub 2016 Dec 1.

PMID:
27960434
13.

Reactive-Atom Scattering from Liquid Crystals at the Liquid-Vacuum Interface: [C12mim][BF4] and 4-Cyano-4'-Octylbiphenyl (8CB).

Purcell SM, Tesa-Serrate MA, Marshall BC, Bruce DW, D'Andrea L, Costen ML, Slattery JM, Smoll EJ Jr, Minton TK, McKendrick KG.

Langmuir. 2016 Oct 4;32(39):9938-9949. Epub 2016 Sep 20.

PMID:
27603521
14.

Enteral tube feeding for individuals with cystic fibrosis: Cystic Fibrosis Foundation evidence-informed guidelines.

Schwarzenberg SJ, Hempstead SE, McDonald CM, Powers SW, Wooldridge J, Blair S, Freedman S, Harrington E, Murphy PJ, Palmer L, Schrader AE, Shiel K, Sullivan J, Wallentine M, Marshall BC, Leonard AR.

J Cyst Fibros. 2016 Nov;15(6):724-735. doi: 10.1016/j.jcf.2016.08.004. Epub 2016 Sep 3. Review.

15.

Cancer risk among lung transplant recipients with cystic fibrosis.

Fink AK, Yanik EL, Marshall BC, Wilschanski M, Lynch CF, Austin AA, Copeland G, Safaeian M, Engels EA.

J Cyst Fibros. 2017 Jan;16(1):91-97. doi: 10.1016/j.jcf.2016.07.011. Epub 2016 Aug 15.

16.

Improving performance in the detection and management of cystic fibrosis-related diabetes in the Mountain West Cystic Fibrosis Consortium.

Liou TG, Jensen JL, Allen SE, Brayshaw SJ, Brown MA, Chatfield B, Koenig J, McDonald C, Packer KA, Peet K, Radford P, Reineke LM, Otsuka K, Wagener JS, Young D, Marshall BC.

BMJ Open Diabetes Res Care. 2016 Apr 29;4(1):e000183. doi: 10.1136/bmjdrc-2015-000183. eCollection 2016.

17.

Risk of Colorectal Cancer After Solid Organ Transplantation in the United States.

Maisonneuve P, Lowenfels AB, Marshall BC.

Am J Transplant. 2016 Aug;16(8):2498. doi: 10.1111/ajt.13833. Epub 2016 May 25. No abstract available.

18.

The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry.

Knapp EA, Fink AK, Goss CH, Sewall A, Ostrenga J, Dowd C, Elbert A, Petren KM, Marshall BC.

Ann Am Thorac Soc. 2016 Jul;13(7):1173-9. doi: 10.1513/AnnalsATS.201511-781OC.

PMID:
27078236
19.

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary.

Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS.

Thorax. 2016 Jan;71(1):88-90. doi: 10.1136/thoraxjnl-2015-207983.

20.

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.

Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS; US Cystic Fibrosis Foundation and European Cystic Fibrosis Society.

Thorax. 2016 Jan;71 Suppl 1:i1-22. doi: 10.1136/thoraxjnl-2015-207360.

21.

A standardized approach to estimating survival statistics for population-based cystic fibrosis registry cohorts.

Sykes J, Stanojevic S, Goss CH, Quon BS, Marshall BC, Petren K, Ostrenga J, Fink A, Elbert A, Stephenson AL.

J Clin Epidemiol. 2016 Feb;70:206-13. doi: 10.1016/j.jclinepi.2015.08.026. Epub 2015 Oct 3.

22.

Advance care planning in cystic fibrosis: Current practices, challenges, and opportunities.

Dellon EP, Chen E, Goggin J, Homa K, Marshall BC, Sabadosa KA, Cohen RI.

J Cyst Fibros. 2016 Jan;15(1):96-101. doi: 10.1016/j.jcf.2015.08.004. Epub 2015 Sep 8.

23.

Baseline Ultrasound and Clinical Correlates in Children with Cystic Fibrosis.

Leung DH, Ye W, Molleston JP, Weymann A, Ling S, Paranjape SM, Romero R, Schwarzenberg SJ, Palermo J, Alonso EM, Murray KF, Marshall BC, Sherker AH, Siegel MJ, Krishnamurthy R, Harned R, Karmazyn B, Magee JC, Narkewicz MR; Cystic Fibrosis Liver Disease Network (CFLD NET).

J Pediatr. 2015 Oct;167(4):862-868.e2. doi: 10.1016/j.jpeds.2015.06.062. Epub 2015 Aug 5.

24.

Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis.

Salsgiver EL, Fink AK, Knapp EA, LiPuma JJ, Olivier KN, Marshall BC, Saiman L.

Chest. 2016 Feb;149(2):390-400. doi: 10.1378/chest.15-0676. Epub 2016 Jan 12.

25.

Outcomes of infants with indeterminate diagnosis detected by cystic fibrosis newborn screening.

Ren CL, Fink AK, Petren K, Borowitz DS, McColley SA, Sanders DB, Rosenfeld M, Marshall BC.

Pediatrics. 2015 Jun;135(6):e1386-92. doi: 10.1542/peds.2014-3698. Epub 2015 May 11.

26.

Atomic-Oxygen-Durable and Electrically-Conductive CNT-POSS-Polyimide Flexible Films for Space Applications.

Atar N, Grossman E, Gouzman I, Bolker A, Murray VJ, Marshall BC, Qian M, Minton TK, Hanein Y.

ACS Appl Mater Interfaces. 2015 Jun 10;7(22):12047-56. doi: 10.1021/acsami.5b02200. Epub 2015 May 21.

PMID:
25945409
27.

Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.

Heltshe SL, Goss CH, Thompson V, Sagel SD, Sanders DB, Marshall BC, Flume PA.

Thorax. 2016 Mar;71(3):223-9. doi: 10.1136/thoraxjnl-2014-206750. Epub 2015 Apr 24.

28.

Experience of care from the perspective of individuals with cystic fibrosis and families: Results from 70 CF Foundation accredited programs in the USA.

Homa K, Sabadosa KA, Marrow LC, Marshall BC.

J Cyst Fibros. 2015 Jul;14(4):515-22. doi: 10.1016/j.jcf.2014.12.011. Epub 2015 Jan 30.

29.

Cystic Fibrosis Foundation and European Cystic Fibrosis Society Survey of cystic fibrosis mental health care delivery.

Abbott J, Elborn JS, Georgiopoulos AM, Goldbeck L, Marshall BC, Sabadosa KA, Smith BA, Quittner AL.

J Cyst Fibros. 2015 Jul;14(4):533-9. doi: 10.1016/j.jcf.2014.12.015. Epub 2015 Jan 12.

30.

Utilization of antibiotics for methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.

Zobell JT, Epps KL, Young DC, Montague M, Olson J, Ampofo K, Chin MJ, Marshall BC, Dasenbrook E.

Pediatr Pulmonol. 2015 Jun;50(6):552-9. doi: 10.1002/ppul.23132. Epub 2015 Jan 5.

PMID:
25559432
31.

Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection.

Mogayzel PJ Jr, Naureckas ET, Robinson KA, Brady C, Guill M, Lahiri T, Lubsch L, Matsui J, Oermann CM, Ratjen F, Rosenfeld M, Simon RH, Hazle L, Sabadosa K, Marshall BC; Cystic Fibrosis Foundation Pulmonary Clinical Practice Guidelines Committee.

Ann Am Thorac Soc. 2014 Dec;11(10):1640-50. doi: 10.1513/AnnalsATS.201404-166OC. Review.

PMID:
25549030
32.

Opportunities for cystic fibrosis care teams to support treatment adherence.

Riekert KA, Eakin MN, Bilderback A, Ridge AK, Marshall BC.

J Cyst Fibros. 2015 Jan;14(1):142-8. doi: 10.1016/j.jcf.2014.10.003. Epub 2014 Oct 24.

33.

Children and young adults with CF in the USA have better lung function compared with the UK.

Goss CH, MacNeill SJ, Quinton HB, Marshall BC, Elbert A, Knapp EA, Petren K, Gunn E, Osmond J, Bilton D.

Thorax. 2015 Mar;70(3):229-36. doi: 10.1136/thoraxjnl-2014-205718. Epub 2014 Sep 25.

34.

Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry.

MacKenzie T, Gifford AH, Sabadosa KA, Quinton HB, Knapp EA, Goss CH, Marshall BC.

Ann Intern Med. 2014 Aug 19;161(4):233-41. doi: 10.7326/M13-0636.

35.

Highly effective cystic fibrosis clinical research teams: critical success factors.

Retsch-Bogart GZ, Van Dalfsen JM, Marshall BC, George C, Pilewski JM, Nelson EC, Goss CH, Ramsey BW.

J Gen Intern Med. 2014 Aug;29 Suppl 3:S714-23. doi: 10.1007/s11606-014-2896-8.

36.

Infection prevention and control guideline for cystic fibrosis: 2013 update.

Saiman L, Siegel JD, LiPuma JJ, Brown RF, Bryson EA, Chambers MJ, Downer VS, Fliege J, Hazle LA, Jain M, Marshall BC, O'Malley C, Pattee SR, Potter-Bynoe G, Reid S, Robinson KA, Sabadosa KA, Schmidt HJ, Tullis E, Webber J, Weber DJ; Cystic Fibrous Foundation; Society for Healthcare Epidemiology of America.

Infect Control Hosp Epidemiol. 2014 Aug;35 Suppl 1:S1-S67. doi: 10.1086/676882. Epub 2014 Jul 1. No abstract available.

PMID:
25025126
37.
38.

Key findings of the US Cystic Fibrosis Foundation's clinical practice benchmarking project.

Boyle MP, Sabadosa KA, Quinton HB, Marshall BC, Schechter MS.

BMJ Qual Saf. 2014 Apr;23 Suppl 1:i15-i22. doi: 10.1136/bmjqs-2013-002369. Review.

PMID:
24608546
39.

Healthcare improvement is incomplete until it is published: the cystic fibrosis initiative to support scholarly publication.

Stevens DP, Marshall BC.

BMJ Qual Saf. 2014 Apr;23 Suppl 1:i104-7. doi: 10.1136/bmjqs-2014-002844.

PMID:
24608545
40.

A decade of healthcare improvement in cystic fibrosis: lessons for other chronic diseases.

Stevens DP, Marshall BC.

BMJ Qual Saf. 2014 Apr;23 Suppl 1:i1-2. doi: 10.1136/bmjqs-2014-002871. Review. No abstract available.

PMID:
24608544
41.

Development and validation of a cystic fibrosis patient and family member experience of care survey.

Homa K, Sabadosa KA, Nelson EC, Rogers WH, Marshall BC.

Qual Manag Health Care. 2013 Apr-Jun;22(2):100-16. doi: 10.1097/QMH.0b013e31828bc3bc.

PMID:
23542365
42.

Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data?

Scully MA, Cwik VA, Marshall BC, Ciafaloni E, Wolff JM, Getchius TS, Griggs RC.

Neurology. 2013 Feb 5;80(6):583-9. doi: 10.1212/WNL.0b013e318282334e. Review.

43.

Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States.

Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB.

J Natl Cancer Inst. 2013 Jan 16;105(2):122-9. doi: 10.1093/jnci/djs481. Epub 2012 Nov 24.

PMID:
23178438
44.

A preliminary evaluation of the effectiveness of the Cystic Fibrosis Foundation Mentoring Program for Respiratory Care.

Richards KM, Lester MK, Chin MJ, Marshall BC.

Respir Care. 2013 May;58(5):764-9. doi: 10.4187/respcare.01745.

45.

A cluster of transfusion-associated babesiosis in extremely low birthweight premature infants.

Kumar P, Marshall BC, deBlois G, Koch WC.

J Perinatol. 2012 Sep;32(9):731-3. doi: 10.1038/jp.2012.33.

PMID:
22931962
46.

Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa.

Saiman L, Mayer-Hamblett N, Anstead M, Lands LC, Kloster M, Goss CH, Rose LM, Burns JL, Marshall BC, Ratjen F; AZ0004 Macrolide Study Team.

Pediatr Pulmonol. 2012 Jul;47(7):641-8. doi: 10.1002/ppul.21601. Epub 2012 Jan 3.

PMID:
22684984
47.

An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation.

Tangpricha V, Kelly A, Stephenson A, Maguiness K, Enders J, Robinson KA, Marshall BC, Borowitz D; Cystic Fibrosis Foundation Vitamin D Evidence-Based Review Committee.

J Clin Endocrinol Metab. 2012 Apr;97(4):1082-93. doi: 10.1210/jc.2011-3050. Epub 2012 Mar 7.

PMID:
22399505
48.

Validation and use of a parametric model for projecting cystic fibrosis survivorship beyond observed data: a birth cohort analysis.

Jackson AD, Daly L, Jackson AL, Kelleher C, Marshall BC, Quinton HB, Fletcher G, Harrington M, Zhou S, McKone EF, Gallagher C, Foley L, Fitzpatrick P.

Thorax. 2011 Aug;66(8):674-9. doi: 10.1136/thoraxjnl-2011-200038. Epub 2011 Jun 8.

49.

A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients.

Zobell JT, Young DC, Waters CD, Ampofo K, Cash J, Marshall BC, Olson J, Chatfield BA.

Pediatr Pulmonol. 2011 Oct;46(10):987-90. doi: 10.1002/ppul.21467. Epub 2011 Apr 25.

PMID:
21520438
50.

Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society.

Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, Robinson KA, Sabadosa KA, Stecenko A, Slovis B; CFRD Guidelines Committee.

Diabetes Care. 2010 Dec;33(12):2697-708. doi: 10.2337/dc10-1768. No abstract available.

Supplemental Content

Loading ...
Support Center